Stock Taper 
Puma Biotechnology, Inc. develops and commercializes cancer treatments, including neratinib for HER2-positive breast cancer and solid tumors, through licensing agreements, headquartered in Los Angeles since 2010.
NERLYNX, developed by Puma Biotechnology, is an oral medication for extended adjuvant treatment of early-stage HER2-positive breast cancer.
In a significant milestone for the company, Puma Biotechnology was added to the NASDAQ Biotechnology Index (NBI) in December 2025. This inclusion was cited by the company as an important recognition of its commercial execution and clinical progress, enhancing its visibility within the investment community and capping a year that saw significant stock price appreciation.
Throughout 2025, Puma Biotechnology has strategically prioritized the advancement of its pipeline candidate, alisertib, an Aurora Kinase A inhibitor. The company's focus has been on the execution of two key Phase II clinical trials, ALISCA-Lung1 for small-cell lung cancer and ALISCA-Breast1 for hormone receptor-positive breast cancer, with the goal of establishing a second revenue-generating product and reducing its reliance on its sole commercial drug, NERLYNX.
LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology announced the grant of an inducement award to one new hire in Sept. 2026, as required under Nasdaq Listing Rule 5635(c)(4).
Overall rating: A
| PEER | PRICE | |
|---|---|---|
 TNGX | $22.10 | COMPARE |
 NUVB | $4.75 | COMPARE |
 ORIC | $11.87 | COMPARE |
 AVBP | $16.46 | COMPARE |
 VSTM | $7.98 | COMPARE |
 ALLO | $1.47 | COMPARE |
 AVIR | $5.05 | COMPARE |
 ARCT | $13.26 | COMPARE |
